
Orlando, FL--Recent preclinical evidence now suggests that administering androgen deprivation therapy (ADT) concurrently with paclitaxel (Taxol) is more effective than sequential treatment in androgen-dependent prostate cancer. In a study presented at the 2005 American Society of Clinical Oncology annual meeting, both time to tumor progression and time to sacrifice were significantly improved in mice treated with the combination therapy compared with sequential therapy.
